Biopharma · FDA Approvals · Stock

YARW Yarrow Bioscience

Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to devel…

Assets on file: YB-101

Start live analysis of YARW Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for YARW, including recently decided ones.

December 2027

Dec 2027

~ Dec 2027

YAYARWYarrow Bioscience, Inc.

YB-101: Phase 2 trial NCT07682896 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for YARW, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 30, 2026

03:24 PM

YAYARWYarrow Bioscience, Inc.

YB-101 · NCT07682896 registry update

countries: {'total_sites': 29, 'us_sites': 27} → {'total_sites': 32, 'us_sites': 29}

Trial registry changeClinicalTrials.gov

Oct 5, 2026

03:24 PM

YAYARWYarrow Bioscience, Inc.

YB-101 · NCT07682896 registry update

countries: {'total_sites': 30, 'us_sites': 28} → {'total_sites': 29, 'us_sites': 27}

Trial registry changeClinicalTrials.gov

Sep 10, 2026

08:01 PM

YAYARWYarrow Bioscience, Inc.

Yarrow Bioscience: YB-101 Phase 2a readout in Graves' Disease expected 2H 2027

The September 2026 corporate overview states that the combined Phase 2a/2b Graves' Disease trial was initiated in Q2 2026 and that the Phase 2a proof-of-concept readout is anticipated in 2H 2027. It also notes that GenSci is conducting ongoing Phase 1 studies in both GD and TED in China, with GD SAD data and TED MAD topline data expected in 2H 2027.

Trial registry changeSEC 8-K